Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives.
暂无分享,去创建一个
[1] D. Brutsaert,et al. Diastolic failure: pathophysiology and therapeutic implications. , 1993, Journal of the American College of Cardiology.
[2] M. Davies,et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. , 2001, Human reproduction.
[3] J. Shaw,et al. Waist circumference, waist–hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults , 2003, Journal of internal medicine.
[4] M. Matsuda,et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. , 2002, Diabetes.
[5] Diederick E Grobbee,et al. Carotid intima–media thickness, arterial stiffness and risk of cardiovascular disease: current evidence , 2002, Journal of hypertension.
[6] S. Daya,et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. , 1999, Human reproduction.
[7] A. Pfeiffer,et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome , 2004 .
[8] A. Tavridou,et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[9] Constance K Haan,et al. Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.
[10] J. Connell,et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. , 2001, The Journal of clinical endocrinology and metabolism.
[11] G. Davı̀,et al. Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.
[12] W. Dodson,et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. , 1999, The Journal of clinical endocrinology and metabolism.
[13] G. London,et al. Arterial stiffness and function in end-stage renal disease. , 2004, Advances in chronic kidney disease.
[14] Richard Kahn,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.
[15] J. Cameron,et al. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[16] B. Strauer,et al. Left Ventricular Diastolic Dysfunction as an Early Manifestation of Diabetic Cardiomyopathy , 2002, Cardiology.
[17] P. Hardiman,et al. Internal carotid artery haemodynamics in women with polycystic ovaries. , 2000, Clinical science.
[18] T. Key,et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. , 1998, The Journal of clinical endocrinology and metabolism.
[19] G. Conway,et al. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome , 1992, Clinical endocrinology.
[20] A. Baron. Insulin resistance and vascular function. , 2002, Journal of diabetes and its complications.
[21] N. Goldenberg,et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. , 2003, Metabolism: clinical and experimental.
[22] E. Bixler,et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. , 2001, The Journal of clinical endocrinology and metabolism.
[23] C. Berne,et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state? , 1996, Human reproduction.
[24] G. Chrousos,et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. , 2005, The Journal of clinical endocrinology and metabolism.
[25] Paul Zimmet,et al. The metabolic syndrome—a new worldwide definition , 2005, The Lancet.
[26] G. Watts,et al. Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the 'recoupling hypothesis'. , 2004, QJM : monthly journal of the Association of Physicians.
[27] D. Meeking,et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS) , 2005, Journal of Clinical Pathology.
[28] M. Sampson,et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI‐1) activity in lean women with and without the polycystic ovary syndrome , 1996, Clinical endocrinology.
[29] E. Barrett-Connor,et al. Prospective study of endogenous sex hormones and fatal cardiovascular disease in postmenopausal women , 1995, BMJ.
[30] C. Giannarelli,et al. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. , 2005, Thrombosis research.
[31] A. von Eckardstein,et al. Androgens and coronary artery disease. , 2003, Endocrine reviews.
[32] P. V. van Kesteren,et al. Mortality and morbidity in transsexual subjects treated with cross‐sex hormones , 1997, Clinical endocrinology.
[33] V. de Leo,et al. Clinical, endocrine and metabolic effects of acarbose, an alpha-glucosidase inhibitor, in PCOS patients with increased insulin response and normal glucose tolerance. , 2001, Human reproduction.
[34] F. Orio,et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.
[35] B. Corenblum,et al. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. , 2000, The Journal of clinical endocrinology and metabolism.
[36] A. Oberg,et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.
[37] L. Kuller,et al. Evidence for Association Between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[38] J. Lekakis,et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. , 2005, European journal of endocrinology.
[39] D. Panidis,et al. Serum adiponectin levels in women with polycystic ovary syndrome. , 2003, Human reproduction.
[40] H. Yki-Järvinen. Insulin resistance and endothelial dysfunction. , 2003, Best practice & research. Clinical endocrinology & metabolism.
[41] H. White,et al. Association between Polycystic Ovaries and Extent of Coronary Artery Disease in Women Having Cardiac Catheterization , 1997, Annals of Internal Medicine.
[42] F. Orio,et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. , 2004, The Journal of clinical endocrinology and metabolism.
[43] A Tremblay,et al. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. , 1990, Arteriosclerosis.
[44] O. Zinder,et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.
[45] Z. Katusic. Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? , 2001, American journal of physiology. Heart and circulatory physiology.
[46] A. Lanzone,et al. Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome. , 2003, Human reproduction.
[47] M. Boscaro,et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome , 2004, Journal of endocrinological investigation.
[48] D. Playford,et al. SPECIAL ARTICLE: NON‐INVASIVE MEASUREMENT OF ENDOTHELIAL FUNCTION , 1998, Clinical and experimental pharmacology & physiology.
[49] G. de Simone,et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. , 2002, Journal of the American College of Cardiology.
[50] K. Segal,et al. Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome , 1989, Diabetes.
[51] A. Balen,et al. Clinical manifestations and insulin resistance (IR) in polycystic ovary syndrome (PCOS) among South Asians and Caucasians: is there a difference? , 2002, Clinical endocrinology.
[52] L. Kuller,et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. , 1998, Journal of clinical epidemiology.
[53] P. McKeigue,et al. Cardiovascular disease in women with polycystic ovary syndrome at long‐term follow‐up: a retrospective cohort study , 2000, Clinical endocrinology.
[54] A. Baron,et al. Polycystic Ovary Syndrome Is Associated With Endothelial Dysfunction , 2001, Circulation.
[55] S. Johansson,et al. Polycystic ovary syndrome and risk for myocardial infarction: Evaluated from a risk factor model based on a prospective population study of women , 1992, Acta obstetricia et gynecologica Scandinavica.
[56] D. Playford,et al. Non-invasive measurement of endothelial function , 1998 .
[57] J. Connell,et al. Altered vascular function in young women with polycystic ovary syndrome. , 2002, The Journal of clinical endocrinology and metabolism.
[58] R. Norman,et al. Metformin in polycystic ovary syndrome: systematic review and meta-analysis , 2003, BMJ : British Medical Journal.
[59] L. Selvaggi,et al. The Plasma Homocysteine Levels Are Increased in Polycystic Ovary Syndrome , 2002, Gynecologic and Obstetric Investigation.
[60] S. Johansson,et al. Hemostatic and metabolic variables in women with polycystic ovary syndrome. , 1994, Fertility and sterility.
[61] B. Fauser,et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.
[62] J. K. Lloyd,et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.
[63] R. Fox. Prevalence of a positive family history of type 2 diabetes in women with polycystic ovarian disease. , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[64] A. Dyer,et al. Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. , 2004, JAMA.
[65] A. Baron,et al. Vascular function, insulin resistance and fatty acids , 2002, Diabetologia.
[66] D. Jakubowicz,et al. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. , 1998, The Journal of clinical endocrinology and metabolism.
[67] J. Manson,et al. Menstrual cycle irregularity and risk for future cardiovascular disease. , 2002, The Journal of clinical endocrinology and metabolism.
[68] R. Rizza. Androgen effect on insulin action and glucose metabolism. , 2000, Mayo Clinic proceedings.
[69] M. Adams,et al. Effects of androgens on coronary artery atherosclerosis and atherosclerosis-related impairment of vascular responsiveness. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[70] L. Kuller,et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. , 1996, American journal of obstetrics and gynecology.
[71] M. Harma,et al. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. , 2001, Clinical biochemistry.
[72] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[73] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[74] J. Roman,et al. Peroxisome Proliferator-Activated Receptor &ggr; Ligands Increase Release of Nitric Oxide From Endothelial Cells , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[75] A. Pfeiffer,et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. , 2004, European journal of endocrinology.
[76] A. Baron,et al. Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.
[77] A. Kitabchi,et al. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. , 1980, The Journal of clinical endocrinology and metabolism.
[78] A. Kunselman,et al. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. , 2001, The American journal of medicine.
[79] Judith R. Rager,et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.
[80] P. Claman. Men at risk: occupation and male infertility. , 2004, Fertility and sterility.
[81] P. Björntorp,et al. Anthropometric variables and metabolism in polycystic ovarian disease. , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[82] Endogenous androgens and carotid intimal-medial thickness in women. , 1999, The Journal of clinical endocrinology and metabolism.
[83] T. Kılıç,et al. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. , 2005, Human reproduction.
[84] D. Webb,et al. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. , 1996, Circulation.
[85] David Handelsman,et al. Androgens and cardiovascular disease. , 2003, Endocrine reviews.
[86] L. Kuller,et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[87] G. Watts,et al. Ventricular dysfunction in early diabetic heart disease: detection, mechanisms and significance. , 2003, Clinical science.
[88] E. Diamanti-Kandarakis,et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. , 2001, The Journal of clinical endocrinology and metabolism.
[89] P. Iozzo,et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. , 2002, Diabetes.
[90] A. Malhotra,et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. , 2001, The Journal of clinical endocrinology and metabolism.
[91] C. Duman,et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. , 2004, The Journal of clinical endocrinology and metabolism.
[92] P Vallance,et al. Heterogenous Nature of Flow-Mediated Dilatation in Human Conduit Arteries In Vivo: Relevance to Endothelial Dysfunction in Hypercholesterolemia , 2001, Circulation research.